Kyoto University researchers have regenerated neural stem cells in an adult mouse and improved its cognitive function through its method, dubbed "iPaD."
The test results were equivalent to turning a 60-year-old-human's neural stem cells into those of a teenager.
However, there are challenges in applying the procedure to humans because the mouse’s genetic engineering involved using a virus to inject the genes into the brain.
The research team’s leader, visiting professor Ryoichiro Kageyama, said they would continue to see if the procedure can be applied to humans.
The team will now test its iPaD method on marmosets to determine if its applicability to primates.
The ability to multiply embryonic neural stem cells to increase the number of nerve cells weakens with age. That, in turn, results in reduced cognitive function.
The iPaD method maximizes the activation of the neural stem cells by combining the infant mice’s most active genes with a restraining function of the adult mice’s most active genes.
The engineered neural stem cells in an adult mouse became more active with the neural stem cells continuing to multiply for about three months.
|Consequently, the adult mouse improved its cognitive function with the increase in neural stem cell multiplication.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities
Visa to Move European Headquarters to London’s Canary Wharf 



